Search clinical trials for: PD-1 knockout

Total 14875 results

Fujian Cancer Hospital

Not yet recruiting

Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy

NSCLC Stage IV

China
Shanghai Zhongshan Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Neoadjuvant Chemoradiation Plus PD-1 Antibody(SHR-1210) in Locally Advanced Proximal Stomach Adenocarcinoma (Neo-PLANET)

Gastric Adenocarcinoma

China
Johnson & Johnson Healthcare Products Division...

Completed

Safety Study for an All-in-One Body and Personal Lubricant

Lubricating Agents

United States
Ningbo Cancer Hospital

Unknown

PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies

Advanced Cancer | Solid Tumor, Adult

China
Sichuan Baili Pharmaceutical Co., Ltd.
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer

Extensive-stage Small-cell Lung Cancer

China
Huabo Biopharm Co., Ltd.

Recruiting

A Study of HB0025 Injection in Patients With Advanced Renal Cancer

Renal Cancer

China
Cancer Institute and Hospital, Chinese Academy...
Peking University Cancer Hospital & Institute; Affiliated Cancer Hospital &... and other collaborators

Recruiting

Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL

Early-stage | Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type

China
Ruijin Hospital

Recruiting

Local Radiotherapy in Combination With Immunotherapy in Advanced Solid Tumors Patients

Solid Tumor

China
Ruijin Hospital

Recruiting

PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT

Lymphoma, Large B-Cell, Diffuse | Chemotherapy | Transplantation

China
Xiangya Hospital of Central South University

Active, not recruiting

Efficacy and Safety Study of Cardunilizumab in Soft Tissue Sarcoma

Sarcoma, Soft Tissue

China
Shanghai Changzheng Hospital

Unknown

Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal Cancer

Colorectal Cancer | Immunotherapy

China
Shanghai Zhongshan Hospital

Unknown

Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant

Liver Transplantation | Hepatocellular Carcinoma

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study

Advanced Hepatocellular Carcinoma

China
Second Affiliated Hospital of Soochow University

Recruiting

A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer

Advanced Solid Tumor | Refractory Tumor

China
MultiVir, Inc.

Unknown

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Lymphoma | Solid Tumor

United States
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma

United States
University Hospital, Basel, Switzerland
GMP network of Basel

Completed

Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma (BaseTIL)

Advanced Melanoma

Switzerland
Zhongshan Hospital Xiamen University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis：Single-arm, Prospective Clinical Study

Stage IV Gastric Cancer With Metastasis
Hoffmann-La Roche

Completed

A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens

Carcinoma, Non-Small-Cell Lung | Carcinoma, Small Cell

United Kingdom, Czechia, Germany, Poland, Spain, Switzerland
St. Jude Children's Research Hospital
SpringWorks Therapeutics, Inc.

Recruiting

SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma

Low-Grade Glioma | Recurrent Low-Grade Glioma | Progressive Low-Grade Glioma

United States
Fresenius Medical Care Deutschland GmbH
Winicker Norimed GmbH; James Motta, Clinical Research Associate (CRA)

Completed

Comparison of Efficacy and Tolerability of APD Treatment With Different PD Cyclers

Renal Failure | End Stage Renal Disease

Chile
University of Colorado, Boulder
National Institute of Mental Health (NIMH); Emory University; Kaiser Permanente

Completed

Mindfulness-Based Cognitive Therapy for the Prevention of Perinatal Depressive Relapse/Recurrence

Depression | Postpartum Depression | Pregnancy

United States
Baodong Qin

Unknown

Effect of Chemotherapy on PD-L1 in NSCLC

Chemotherapy | Immunotherapy | PD-L1

China
Tatarstan Cancer Center

Unknown

Study Estimating Association Between Germline Mutations and PD-L1 Expression in Breast Cancer

Hereditary Breast Cancer

Russian Federation
Innovative Diagnostics Inc

Terminated

Rapid Point-of-Care Salivary Diagnostic for Periodontal Health

Gingivitis | Periodontal Disease

United States
Pfizer

Withdrawn

6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)

Generalized Anxiety Disorder

United States
Pfizer

Completed

A Double-blind, Parallel Group, Placebo-Controlled Outpatient Trial of PD 00200390 in Adults With Nonrestorative Sleep

Nonrestorative Sleep

United States, Canada
Pfizer

Completed

A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Outpatient Trial Of PD 0200390 In Adults With Primary Insomnia

Insomnia

United States, Canada
Louisiana State University Health Sciences Center...

Completed

Designer Dialysis Peritoneal Dialysis

Quality of Life | Peritoneal Dialysis
photonamic GmbH & Co. KG

Terminated

Fluorescence-guided Resection in Breast Cancer

Breast Tumour

Germany
University of Chile
Comisión Nacional de Investigación Científica y Tecnológica

Unknown

Physical Activity Enhancement Using Pedometers in COPD

COPD

Chile
Pfizer

Terminated

A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)

Generalized Anxiety Disorder

United States
Pfizer

Completed

A Dose-ranging, Multicenter Polysomnography Trial of PD 0200390 in Adults With Primary Insomnia

Primary Insomnia

United States
Pfizer

Completed

A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis

Pharmacokinetics | Renal Dialysis

United States
RenJi Hospital

Not yet recruiting

Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy (sPLENTY-pc)

Pediatric Cancer | Liver Cancer | Hepatoblastoma | Pediatric Solid Tumor | Transitional Cell Tumor

China
Chen Xiaoping

Recruiting

Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation

Hepatocellular Carcinoma

China
LI XIN-XIANG

Not yet recruiting

A Combination Therapy Including Anti-PD-1 Immunotherapy in Rectal Cancer With Refractory Distal Metastasis (Miracle-2)

Advanced Rectal Cancer | Distal Metastasis

China
Lei Li

Recruiting

PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer

Recurrent Cervical Carcinoma | Radiotherapy | Immune Checkpoint Inhibitors | Overall Survival | Anti-programmed Death-1 Antibody | Metastatic Cervical Carcinoma | Persistent Advanced Cervical Carcinoma | Objective Remission Rate | Progression-free Survival | Severe Adverse Events

China
Sichuan Cancer Hospital and Research Institute

Active, not recruiting

PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial

Nasopharyngeal Carcinoma | Chemoradiotherapy | PD-1 Inhibitors

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Unknown

Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
The Affiliated Hospital of Qingdao University

Unknown

PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC

NSCLC Stage IV | PD-1 | ARID1A

China
Third Military Medical University

Unknown

CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma

Burkitt Lymphoma | Acute Lymphoblastic Leukemia
Yunnan Cancer Hospital

Recruiting

The Efficacy of Watch and Wait Strategy or Surgery After Neoadjuvant Immunotherapy for Locally Advanced Colorectal Cancer With dMMR/MSI-H Guided by MRD Dynamic Monitoring: A Single-center, Open-label, Prospective, Phase II Clinical Trial. (WINDOW)

Clinical Complete Response Rate With Negative MRD

China
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Immunotherapy in Upper Tract Urothelial Carcinoma (VESUVIO)

Urothelial Carcinoma
Shanghai Chest Hospital

Not yet recruiting

Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE) (RICE)

Chemotherapy | Immunotherapy | Concurrent Chemoradiotherapy | Esophageal Squamous Cell Carcinomas
Sun Yat-sen University

Recruiting

Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Tang-Du Hospital

Enrolling by invitation

Prospective Cohort Study of Neoadjuvant Therapy With Sintilimab (PD-1 Inhibitor) Combined With Chemotherapy in Resectable ESCC

Resectable Esophageal Squamous Cell Carcinoma

China
Henan Cancer Hospital
Cttq

Unknown

Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody

Advanced Solid Tumor

China
Ruijin Hospital

Not yet recruiting

PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma (ENKTL)

NK-T-Cell Lymphoma, Extranodal

China
Georgiamune Inc

Recruiting

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

Solid Tumor | Melanoma Stage IV

United States

Search clinical trials for: PD-1 knockout

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations